Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vulvo Vaginal Atrophy Clear all

Conditions: Postmenopausal Vulvovaginal Atrophy
Interventions: WC3011 Estradiol Vaginal Cream, Vehicle; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 70
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 58 more

Conditions: Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
Interventions: 5% sinecatechins ointment, Placebo, 10% sinecatechins ointment; Drug
Lead sponsor: GTO Pharmaceutical, LLC; Other
Eligibility: 20 Years to 70 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: New York, New York • Nyack, New York

Conditions: Menopause
Interventions: DR-2041a, DR-2041b, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 97
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more

Conditions: Breast Cancer, Vulvovaginal Signs and Symptoms, Sexual Desire Disorder, Body Image
Interventions: Hyaluronic acid (HLA) Vaginal Moisturizer, Polycarbophil Vaginal Moisturizer, Hypnotic Relaxation, Progressive Muscle Relaxation (PMR); Device · Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Vulvovaginal Atrophy
Interventions: Laser treatment; Device
Lead sponsor: El. En. SpA; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Palo Alto, California • West Chester, Ohio

Conditions: Stress Urinary Incontinence, Vulvovaginal Signs and Symptoms
Interventions: MorpheusV Applicator; Device
Lead sponsor: InMode MD Ltd.; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Alpharetta, Georgia • Bluffton, South Carolina

Conditions: Menopause
Interventions: Synthetic Conjugated estrogens, B, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 38
States / cities: Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more

Conditions: Breast Cancer, Hot Flashes, Sexual Dysfunction, Fertility, Contraception
Interventions: Reproductive Health Survivorship Care Plan (SCPR), Control; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Sexual Dysfunction, Physiological, Body Image, Libido; Loss, Aversion
Interventions: Hypnotic Relaxation Intervention (HRI), Vulvovaginal Atrophy (VVA); Other · Device
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Vulvovaginal Atrophy, Menopause, Genitourinary Syndrome of Menopause
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years and older · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Vaginal Atrophy
Interventions: MorpheusV Applicator; Device
Lead sponsor: InMode MD Ltd.; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Newport Beach, California • Knoxville, Tennessee

Conditions: Vulvovaginal Atrophy, Dyspareunia
Interventions: Ospemifene; Drug
Lead sponsor: Sue Goldstein; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atrophy, Vaginal Atrophy, Genital Diseases, Female
Interventions: Pixel CO2 Laser System; Procedure
Lead sponsor: Alma Lasers Inc.; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions: Estradiol Vaginal Capsule (EVC), Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more

Conditions: Vulvovaginal Atrophy, Urinary Incontinence, Sexual Dysfunction
Interventions: Treatment with BTL-785F and HPM-6000UF Devices; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 30 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Mission Viejo, California • Sugar Land, Texas

Conditions: Vulvovaginal Atrophy
Interventions: no intervention; Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Vulvo Vaginal Atrophy (VVA)
Interventions: Lasofoxifene Tartrate; Drug
Lead sponsor: Azure Biotech Inc.; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Vulvovaginal Atrophy
Interventions: WC3011 Estradiol Vaginal Cream; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 64
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more

Conditions: Dyspareunia
Interventions: Prasterone; Drug
Lead sponsor: San Diego Sexual Medicine; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Vulvo Vaginal Atrophy
Interventions: Femarelle; Dietary Supplement
Lead sponsor: Dr. Lila Nachtigall Rapid Medical Research, New York; Other
Eligibility: 40 Years to 85 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Vulvovaginal Atrophy
Interventions: CO2 Laser Treatment; Device
Lead sponsor: SHERRY Thomas; Other
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Agoura Hills, California

Conditions: Menopause, Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy, Menopause Syndrome, Dyspareunia
Interventions: Intrarosa, Placebos; Drug
Lead sponsor: Center for Vulvovaginal Disorders; Other
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions: Estradiol, placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Vaginal Atrophy
Interventions: Placebo, Prasterone (DHEA); Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more

Search by objective public record fields.

Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

WISH, Feasibility of a Factorial Design

Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy

Clinical Evaluation of Fractional Bi-Polar RF for Symptoms of SUI and Vulvovaginal Atrophy

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

Reproductive Health Survivorship Care Plan

Women's Interventions for Sexual Health: WISH

Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM

Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Vulvovaginal Atrophy

Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA

Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

Combination of BTL-785F and HPM-6000UF Devices for Women's Intimate Wellness

High Tone Pelvic Floor Dysfunction

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

A Twelve Week Study to Investigate the Efficacy of Femarelle®, for the Treatment of Post Menopausal Vaginal Atrophy

Fractional Handpiece With CO2 Laser: Fractional Ablative Laser Treatment of Vulvovaginal Atrophy

Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause